{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PI3K\u03b1 inhibitor", "cell apoptosis", "cell cycle arrest", "imidazo[1,2-a]pyridine", "quinazoline"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37047827", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "14"}, "DateRevised": {"Year": "2023", "Month": "04", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "04", "Day": "06"}], "Language": ["eng"], "ELocationID": ["6851", "10.3390/ijms24076851"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "24", "Issue": "7", "PubDate": {"Year": "2023", "Month": "Apr", "Day": "06"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3K\u03b1 Inhibition.", "Abstract": {"AbstractText": ["Aberrant expression of the phosphatidylinositol 3-kinase (PI3K) signalling pathway is often associated with tumourigenesis, progression and poor prognosis. Hence, PI3K inhibitors have attracted significant interest for the treatment of cancer. In this study, a series of new 6-(imidazo[1,2-a]pyridin-6-yl)quinazoline derivatives were designed, synthesized and characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR and HRMS spectra analyses. In the in vitro anticancer assay, most of the synthetic compounds showed submicromolar inhibitory activity against various tumour cell lines, among which <b>13k</b> is the most potent compound with IC<sub>50</sub> values ranging from 0.09 \u03bc\u039c to 0.43 \u03bc\u039c against all the tested cell lines. Moreover, <b>13k</b> induced cell cycle arrest at G2/M phase and cell apoptosis of HCC827 cells by inhibition of PI3K\u03b1 with an IC<sub>50</sub> value of 1.94 nM. These results suggested that compound <b>13k</b> might serve as a lead compound for the development of PI3K\u03b1 inhibitor."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Li", "ForeName": "Mei", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Wang", "ForeName": "Daoping", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Li", "ForeName": "Qing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Luo", "ForeName": "Fang", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Zhong", "ForeName": "Ting", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Wu", "ForeName": "Hongshan", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Xiong", "ForeName": "Liang", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Yuan", "ForeName": "Meitao", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Su", "ForeName": "Mingzhi", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Fan", "ForeName": "Yanhua", "Initials": "Y"}], "GrantList": [{"GrantID": "202001", "Agency": "Merit-based Funding Program for Innovation and Entrepreneurship of High-level Overseas Talents of Guizhou Province", "Country": ""}, {"GrantID": "QKH-zk [2022]030", "Agency": "Natural Science Foundation of Guizhou Provincial Science and Technology Projects", "Country": ""}, {"GrantID": "QKHPTRC[2018]5779-58", "Agency": "Science and Technology Plan Project of Guizhou Province, China", "Country": ""}, {"GrantID": "21907020", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "22167010", "Agency": "National Natural Science Foundation of China", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "EC 2.7.1.-", "NameOfSubstance": "Phosphatidylinositol 3-Kinases"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Quinazolines"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Drug Design"}], "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Hernandez-Aya L.F., Gonzalez-Angulo A.M. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011;16:404\u2013414. doi: 10.1634/theoncologist.2010-0402.", "ArticleIdList": ["10.1634/theoncologist.2010-0402", "PMC3228119", "21406469"]}, {"Citation": "Thorpe L.M., Yuzugullu H., Zhao J.J. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer. 2015;15:7\u201324. doi: 10.1038/nrc3860.", "ArticleIdList": ["10.1038/nrc3860", "PMC4384662", "25533673"]}, {"Citation": "Mayer I.A., Arteaga C.L. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu. Rev. Med. 2016;67:11\u201328. doi: 10.1146/annurev-med-062913-051343.", "ArticleIdList": ["10.1146/annurev-med-062913-051343", "26473415"]}, {"Citation": "Tewari D., Patni P., Bishayee A., Sah A.N., Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin. Cancer. Biol. 2022;80:1\u201317. doi: 10.1016/j.semcancer.2019.12.008.", "ArticleIdList": ["10.1016/j.semcancer.2019.12.008", "31866476"]}, {"Citation": "Yu L., Wei J., Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin. Cancer Biol. 2022;85:69\u201394. doi: 10.1016/j.semcancer.2021.06.019.", "ArticleIdList": ["10.1016/j.semcancer.2021.06.019", "34175443"]}, {"Citation": "Wang J., Hu K., Cai X., Yang B., He Q., Wang J., Weng Q. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta. Pharm. Sin. B. 2022;12:18\u201332. doi: 10.1016/j.apsb.2021.07.023.", "ArticleIdList": ["10.1016/j.apsb.2021.07.023", "PMC8799876", "35127370"]}, {"Citation": "Zhang M., Jang H., Nussinov R. PI3K inhibitors: Review and new strategies. Chem. Sci. 2020;11:5855\u20135865. doi: 10.1039/D0SC01676D.", "ArticleIdList": ["10.1039/D0SC01676D", "PMC7472334", "32953006"]}, {"Citation": "Mazloumi Gavgani F., Smith Arnesen V., Jacobsen R.G., Krakstad C., Hoivik E.A., Lewis A.E. Class I Phosphoinositide 3-Kinase PIK3CA/p110alpha and PIK3CB/p110beta Isoforms in Endometrial Cancer. Int. J. Mol. Sci. 2018;19:3931. doi: 10.3390/ijms19123931.", "ArticleIdList": ["10.3390/ijms19123931", "PMC6321576", "30544563"]}, {"Citation": "Chen W., Dai G., Qian Y., Wen L., He X., Liu H., Gao Y., Tang X., Dong B. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway. Oncol. Rep. 2022;47:11. doi: 10.3892/or.2021.8222.", "ArticleIdList": ["10.3892/or.2021.8222", "34751411"]}, {"Citation": "Tserga A., Chatziandreou I., Michalopoulos N.V., Patsouris E., Saetta A.A. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows. Arch. 2016;469:35\u201343. doi: 10.1007/s00428-016-1938-5.", "ArticleIdList": ["10.1007/s00428-016-1938-5", "27059323"]}, {"Citation": "Knowles M.A., Platt F.M., Ross R.L., Hurst C.D. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009;28:305\u2013316. doi: 10.1007/s10555-009-9198-3.", "ArticleIdList": ["10.1007/s10555-009-9198-3", "PMC2797439", "20013032"]}, {"Citation": "Sweetlove M., Wrightson E., Kolekar S., Rewcastle G.W., Baguley B.C., Shepherd P.R., Jamieson S.M. Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Front. Oncol. 2015;5:135. doi: 10.3389/fonc.2015.00135.", "ArticleIdList": ["10.3389/fonc.2015.00135", "PMC4468830", "26137449"]}, {"Citation": "Vanhaesebroeck B., Perry M.W.D., Brown J.R., Andre F., Okkenhaug K. Author Correction: PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 2021;20:798. doi: 10.1038/s41573-021-00300-7.", "ArticleIdList": ["10.1038/s41573-021-00300-7", "34471263"]}, {"Citation": "Yang J., Nie J., Ma X., Wei Y., Peng Y., Wei X. Targeting PI3K in cancer: Mechanisms and advances in clinical trials. Mol. Cancer. 2019;18:26. doi: 10.1186/s12943-019-0954-x.", "ArticleIdList": ["10.1186/s12943-019-0954-x", "PMC6379961", "30782187"]}, {"Citation": "Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. Int. J. Med. Chem. 2014;2014:395637. doi: 10.1155/2014/395637.", "ArticleIdList": ["10.1155/2014/395637", "PMC4321853", "25692041"]}, {"Citation": "Dhuguru J., Ghoneim O.A. Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents. Molecules. 2022;27:2294. doi: 10.3390/molecules27072294.", "ArticleIdList": ["10.3390/molecules27072294", "PMC9000668", "35408693"]}, {"Citation": "Hameed A., Al-Rashida M., Uroos M., Ali S.A., Arshia, Ishtiaq M., Khan K.M. Quinazoline and quinazolinone as important medicinal scaffolds: A comparative patent review (2011\u20132016) Expert. Opin. Ther. Pat. 2018;28:281\u2013297. doi: 10.1080/13543776.2018.1432596.", "ArticleIdList": ["10.1080/13543776.2018.1432596", "29368977"]}, {"Citation": "Ding H.W., Deng C.L., Li D.D., Liu D.D., Chai S.M., Wang W., Zhang Y., Chen K., Li X., Wang J., et al. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kalpha. Eur. J. Med. Chem. 2018;146:460\u2013470. doi: 10.1016/j.ejmech.2018.01.081.", "ArticleIdList": ["10.1016/j.ejmech.2018.01.081", "29407971"]}, {"Citation": "Teng Y., Li X., Ren S., Cheng Y., Xi K., Shen H., Ma W., Luo G., Xiang H. Discovery of novel quinazoline derivatives as potent PI3Kdelta inhibitors with high selectivity. Eur. J. Med. Chem. 2020;208:112865. doi: 10.1016/j.ejmech.2020.112865.", "ArticleIdList": ["10.1016/j.ejmech.2020.112865", "32987316"]}, {"Citation": "Zhou Z., He J., Yang F., Pan Q., Yang Z., Zheng P., Xu S., Zhu W. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. Bioorg. Chem. 2021;112:104848. doi: 10.1016/j.bioorg.2021.104848.", "ArticleIdList": ["10.1016/j.bioorg.2021.104848", "33819737"]}, {"Citation": "Das D., Hong J. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. Eur. J. Med. Chem. 2019;170:55\u201372. doi: 10.1016/j.ejmech.2019.03.004.", "ArticleIdList": ["10.1016/j.ejmech.2019.03.004", "30878832"]}, {"Citation": "Yadav R.R., Guru S.K., Joshi P., Mahajan G., Mintoo M.J., Kumar V., Bharate S.S., Mondhe D.M., Vishwakarma R.A., Bhushan S., et al. 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. Eur. J. Med. Chem. 2016;122:731\u2013743. doi: 10.1016/j.ejmech.2016.07.006.", "ArticleIdList": ["10.1016/j.ejmech.2016.07.006", "27479483"]}, {"Citation": "Fan Y.H., Ding H.W., Liu D.D., Song H.R., Xu Y.N., Wang J. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kalpha inhibition. Bioorg. Med. Chem. 2018;26:1675\u20131685. doi: 10.1016/j.bmc.2018.02.015.", "ArticleIdList": ["10.1016/j.bmc.2018.02.015", "29475582"]}, {"Citation": "Altaher A.M., Adris M.A., Aliwaini S.H., Awadallah A.M., Morjan R.Y. The Anticancer Effects of Novel Imidazo[1,2-a]Pyridine Compounds against HCC1937 Breast Cancer Cells. Asian. Pac. J. Cancer Prev. 2022;23:2943\u20132951. doi: 10.31557/APJCP.2022.23.9.2943.", "ArticleIdList": ["10.31557/APJCP.2022.23.9.2943", "PMC9810306", "36172656"]}, {"Citation": "Dos Santos D.C., Rafique J., Saba S., Grinevicius V., Filho D.W., Zamoner A., Braga A.L., Pedrosa R.C., Ourique F. IP-Se-06, a Selenylated Imidazo[1,2-a]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1alpha and MAPK Signaling Inhibition, Promoting Antiproliferative Effect and Apoptosis in Glioblastoma Cells. Oxid. Med. Cell. Longev. 2022;2022:3710449. doi: 10.1155/2022/3710449.", "ArticleIdList": ["10.1155/2022/3710449", "PMC8964227", "35360199"]}, {"Citation": "Foki E., Stanisz I., Kadletz L., Kotowski U., Seemann R., Schmid R., Heiduschka G. HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines. Wien. Klin. Wochenschr. 2021;133:26\u201331. doi: 10.1007/s00508-020-01729-3.", "ArticleIdList": ["10.1007/s00508-020-01729-3", "32876741"]}, {"Citation": "Hernandez-Prat A., Rodriguez-Vida A., Juanpere-Rodero N., Arpi O., Menendez S., Soria-Jimenez L., Martinez A., Iarchouk N., Rojo F., Albanell J., et al. Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kalpha Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Mol. Cancer Res. 2019;17:1931\u20131944. doi: 10.1158/1541-7786.MCR-18-0923.", "ArticleIdList": ["10.1158/1541-7786.MCR-18-0923", "31160383"]}, {"Citation": "Singh D., Yodun T., Kumar G., Ahmad Tali J., Tiwari H., Singh J., Nargotra A., Samykutty A., Singh S., Shankar R. Synthesis of 3-N-/O-/S-methyl-imidazo[1,2-a] pyridine derivatives for caspase-3 mediated apoptosis induced anticancer activity. Bioorg. Chem. 2022;125:105882. doi: 10.1016/j.bioorg.2022.105882.", "ArticleIdList": ["10.1016/j.bioorg.2022.105882", "35660838"]}, {"Citation": "Fan Y., Luo F., Su M., Li Q., Zhong T., Xiong L., Li M., Yuan M., Wang D. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition. Bioorg. Chem. 2023;132:106352. doi: 10.1016/j.bioorg.2023.106352.", "ArticleIdList": ["10.1016/j.bioorg.2023.106352", "36682147"]}, {"Citation": "Li P., Lv H., Zhang B., Duan R., Zhang X., Lin P., Song C., Liu Y. Growth Differentiation Factor 15 Protects SH-SY5Y Cells from Rotenone-Induced Toxicity by Suppressing Mitochondrial Apoptosis. Front. Aging Neurosci. 2022;14:869558. doi: 10.3389/fnagi.2022.869558.", "ArticleIdList": ["10.3389/fnagi.2022.869558", "PMC9201950", "35721026"]}, {"Citation": "Niu H., Wang D., Wen T., Liu H., Jie J., Song L., Li D. Anwuligan inhibits the progression of non-small cell lung cancer via let-7c-3p/PI3K/AKT/mTOR axis. Cancer Med. 2022;22:5382. doi: 10.1002/cam4.5382.", "ArticleIdList": ["10.1002/cam4.5382", "PMC10028152", "36412203"]}, {"Citation": "Yadollahi-Farsani M., Amini-Farsani Z., Moayedi F., Khazaei N., Yaghoobi H. MiR-548k suppresses apoptosis in breast cancer cells by affecting PTEN/PI3K/AKT signaling pathway. IUBMB Life. 2023;75:97\u2013116. doi: 10.1002/iub.2688.", "ArticleIdList": ["10.1002/iub.2688", "36309967"]}, {"Citation": "Yang Z., Cai W., Chen Y., Guo Z., Xiao Z., Zhou T., Cheng Y., Xu F. Jujuboside B Reverse CUMS-Promoted Tumor Progression via Blocking PI3K/Akt and MAPK/ERK and Dephosphorylating CREB Signaling. J. Immunol. Res. 2022;2022:5211368. doi: 10.1155/2022/5211368.", "ArticleIdList": ["10.1155/2022/5211368", "PMC9569198", "36254198"]}, {"Citation": "Lien E.C., Dibble C.C., Toker A. PI3K signaling in cancer: Beyond AKT. Curr. Opin. Cell Biol. 2017;45:62\u201371. doi: 10.1016/j.ceb.2017.02.007.", "ArticleIdList": ["10.1016/j.ceb.2017.02.007", "PMC5482768", "28343126"]}, {"Citation": "Zhu W., Shi L., Gong Y., Zhuo L., Wang S., Chen S., Zhang B., Ke B. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway. Thorac. Cancer. 2022;13:1027\u20131039. doi: 10.1111/1759-7714.14354.", "ArticleIdList": ["10.1111/1759-7714.14354", "PMC8977174", "35178875"]}, {"Citation": "Jiang L., Zhang J., Xu Y., Xu H., Wang M. Treating non-small cell lung cancer by targeting the PI3K signaling pathway. Chin. Med. J. Engl. 2022;135:1272\u20131284. doi: 10.1097/CM9.0000000000002195.", "ArticleIdList": ["10.1097/CM9.0000000000002195", "PMC9433080", "35830272"]}, {"Citation": "Scheffler M., Bos M., Gardizi M., K\u00f6nig K. PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2015;6:1315\u20131326. doi: 10.18632/oncotarget.2834.", "ArticleIdList": ["10.18632/oncotarget.2834", "PMC4359235", "25473901"]}, {"Citation": "Tang W., Jia P., Zuo L., Zhao J. Suppression of CX3CL1 by miR-497-5p inhibits cell growth and invasion through inactivating the ERK/AKT pathway in NSCLC cells. Cell Cycle. 2022;21:1697\u20131709. doi: 10.1080/15384101.2022.2067438.", "ArticleIdList": ["10.1080/15384101.2022.2067438", "PMC9302515", "35485293"]}, {"Citation": "Yan Y., Jin X., Sun H., Pang S., Kong X., Bu J., Xu S. MiR-139-5p Targetedly Regulates YAF2 and Mediates the AKT/P38 MAPK Signaling Pathway to Alleviate the Metastasis of Non-Small Cell Lung Cancer Cells and Their Resistance against Cisplatin. Cancer. Manag. Res. 2021;13:3639\u20133650. doi: 10.2147/CMAR.S254671.", "ArticleIdList": ["10.2147/CMAR.S254671", "PMC8109024", "33981163"]}, {"Citation": "Zheng B., Zheng Y., Zhang N., Zhang Y., Zheng B. Rhoifolin from Plumula Nelumbinis exhibits anti-cancer effects in pancreatic cancer via AKT/JNK signaling pathways. Sci. Rep. 2022;12:5654. doi: 10.1038/s41598-022-09581-3.", "ArticleIdList": ["10.1038/s41598-022-09581-3", "PMC8983741", "35383226"]}, {"Citation": "Rovida E., Tusa I. Targeting MAPK in Cancer 2.0. Int. J. Mol. Sci. 2022;23:5702. doi: 10.3390/ijms23105702.", "ArticleIdList": ["10.3390/ijms23105702", "PMC9143559", "35628511"]}, {"Citation": "Mansour M.A., Lasheen D.S., Gaber H.M., Abouzid K.A.M. Elaborating piperazinyl-furopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3Kalpha) inhibitors to combat pancreatic cancer. RSC Adv. 2020;10:32103\u201332112. doi: 10.1039/D0RA06428A.", "ArticleIdList": ["10.1039/D0RA06428A", "PMC9056536", "35518146"]}, {"Citation": "Koledova Z. 3D Cell Culture: An Introduction. Methods. Mol. Biol. 2017;1612:1\u201311. doi: 10.1007/978-1-4939-7021-6_1.", "ArticleIdList": ["10.1007/978-1-4939-7021-6_1", "28634931"]}, {"Citation": "Langhans S.A. Using 3D in vitro cell culture models in anti-cancer drug discovery. Expert Opin. Drug Discov. 2021;16:841\u2013850. doi: 10.1080/17460441.2021.1912731.", "ArticleIdList": ["10.1080/17460441.2021.1912731", "33823728"]}, {"Citation": "Ravi M., Paramesh V., Kaviya S., Anuradha E., Solomon F. 3D cell culture systems: Advantages and applications. J. Cell. Physiol. 2015;230:16\u201326. doi: 10.1002/jcp.24683.", "ArticleIdList": ["10.1002/jcp.24683", "24912145"]}, {"Citation": "Gu C., Feng J., Waqas A., Deng Y., Zhang Y., Chen W., Long J., Huang S., Chen L. Technological Advances of 3D Scaffold-Based Stem Cell/Exosome Therapy in Tissues and Organs. Front. Cell Dev. Biol. 2021;9:709204. doi: 10.3389/fcell.2021.709204.", "ArticleIdList": ["10.3389/fcell.2021.709204", "PMC8458970", "34568322"]}, {"Citation": "Pashuck E.T., Stevens M. From clinical imaging to implantation of 3D printed tissues. Nat. Biotechnol. 2016;34:295\u2013296. doi: 10.1038/nbt.3503.", "ArticleIdList": ["10.1038/nbt.3503", "26963553"]}, {"Citation": "Wang J., Zhang X., Li X., Zhang Y., Hou T., Wei L., Qu L., Shi L., Liu Y., Zou L., et al. Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. Sci. Rep. 2016;6:24772. doi: 10.1038/srep24772.", "ArticleIdList": ["10.1038/srep24772", "PMC4838868", "27098119"]}, {"Citation": "Kniebs C., Luengen A.E., Guenther D., Cornelissen C.G., Schmitz-Rode T., Jockenhoevel S., Thiebes A.L. Establishment of a Pre-vascularized 3D Lung Cancer Model in Fibrin Gel-Influence of Hypoxia and Cancer-Specific Therapeutics. Front. Bioeng. Biotechnol. 2021;9:761846. doi: 10.3389/fbioe.2021.761846.", "ArticleIdList": ["10.3389/fbioe.2021.761846", "PMC8551668", "34722481"]}, {"Citation": "Han K., Pierce S.E., Li A., Spees K., Anderson G.R., Seoane J.A., Lo Y.H., Dubreuil M., Olivas M., Kamber R.A., et al. CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature. 2020;580:136\u2013141. doi: 10.1038/s41586-020-2099-x.", "ArticleIdList": ["10.1038/s41586-020-2099-x", "PMC7368463", "32238925"]}, {"Citation": "Xiao Z., Osipyan A., Song S., Chen D., Schut R.A., van Merkerk R., van der Wouden P.E., Cool R.H., Quax W.J., Melgert B.N., et al. Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells. J. Med. Chem. 2022;65:2059\u20132077. doi: 10.1021/acs.jmedchem.1c01598.", "ArticleIdList": ["10.1021/acs.jmedchem.1c01598", "PMC8842245", "35041425"]}, {"Citation": "Yang H., Li Q., Su M., Luo F., Liu Y., Wang D., Fan Y. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition. Bioorg. Med. Chem. 2021;46:116346. doi: 10.1016/j.bmc.2021.116346.", "ArticleIdList": ["10.1016/j.bmc.2021.116346", "34403956"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "2", "Day": "15"}, {"Year": "2023", "Month": "3", "Day": "30"}, {"Year": "2023", "Month": "4", "Day": "3"}, {"Year": "2023", "Month": "4", "Day": "14", "Hour": "6", "Minute": "41"}, {"Year": "2023", "Month": "4", "Day": "13", "Hour": "1", "Minute": "14"}, {"Year": "2023", "Month": "4", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "4", "Day": "6"}], "PublicationStatus": "epublish", "ArticleIdList": ["37047827", "PMC10095550", "10.3390/ijms24076851", "ijms24076851"]}}], "PubmedBookArticle": []}